Advertisement
Screener

Krystal Biotech, Inc. (KRYS) Graph

KRYS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue $119.22M; Research and development $14.52M; Selling, general and administrative $39.85M; Operating expenses $60.80M.
  • 2026-03-31: Revenue $116.36M; Research and development $15.33M; Selling, general and administrative $41.01M; Operating expenses $62.67M.
  • 2025-12-31: Revenue $107.11M*; Research and development $14.79M*; Selling, general and administrative $41.45M*; Operating expenses $62.84M*.
  • 2025-09-30: Revenue $97.80M; Research and development $14.59M; Selling, general and administrative $37.58M; Operating expenses $56.43M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$119.22M$14.52M$39.85M$60.80M$11.31M$54.77M
2026-03-31$116.36M$15.33M$41.01M$62.67M$5.51M$55.93M
2025-12-31$107.11M*$14.79M*$41.45M*$62.84M*-$269.00K*$51.40M*
2025-09-30$97.80M$14.59M$37.58M$56.43M-$31.40M$79.36M
2025-06-30$96.04M$14.41M$35.07M$56.64M$8.44M$38.33M
2025-03-31$88.18M$14.26M$32.65M$51.93M$7.86M$35.73M
2024-09-30$83.84M$13.51M$28.67M$61.37M$2.59M$27.18M
2024-06-30$70.28M$15.58M$27.63M$61.72M$477.00K$15.57M
2024-03-31$45.25M$10.96M$26.06M$51.93M$0.00$932.00K
2023-09-30$8.56M$10.63M$23.70M$34.55M$0.00$80.75M
2023-06-30$0.00$12.14M$25.90M$38.05M$0.00-$33.21M
2023-03-31$0.00$12.29M$24.04M$48.82M(m)-$45.30M
2022-09-30$0.00$11.52M$19.93M$31.45M(m)-$29.85M
2022-06-30(m)$10.89M(m)$28.75M(m)-$28.11M
2022-03-31(m)$9.31M(m)$50.22M(m)-$49.97M
2021-09-30(m)$6.08M(m)$15.65M(m)-$15.59M
2021-06-30(m)$6.59M(m)$16.39M(m)-$16.36M
2021-03-31(m)$6.20M(m)$14.35M(m)-$15.81M
2020-09-30(m)$5.10M(m)$9.68M(m)-$9.61M
2020-06-30(m)$3.64M(m)$6.95M(m)-$6.83M
2020-03-31(m)$3.52M(m)$5.95M(m)-$5.34M
2019-09-30(m)$3.88M(m)$5.34M(m)-$4.27M
2019-06-30(m)$4.22M(m)$5.89M(m)-$5.35M
2019-03-31(m)$3.17M(m)$4.69M(m)-$4.11M
2018-09-30(m)$1.91M(m)$2.97M(m)-$2.75M
2018-06-30(m)$1.52M(m)$2.45M(m)-$2.28M
2018-03-31(m)$1.52M(m)$2.28M(m)-$2.15M
2017-09-30(m)$1.35M(m)$2.09M(m)-$5.27M
2017-06-30(m)$446.00K(m)$715.00K(m)-$759.00K
2017-03-31(m)$319.00K(m)$465.00K(m)-$494.00K
2016-09-30(m)$241.00K(m)$322.00K(m)-$322.00K

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$235.58M$29.85M$80.86M$123.47M$16.82M$110.70M
2025-06-30$184.22M$28.67M$67.71M$108.57M$16.30M$74.07M
2024-06-30$115.53M$26.54M$53.69M$113.65M$477.00K$16.50M
2023-06-30$0.00$24.43M$49.94M$86.87M$0.00-$78.51M
2022-06-30(m)$20.20M(m)$78.97M(m)-$78.07M
2021-06-30(m)$12.79M(m)$30.75M(m)-$32.17M
2020-06-30(m)$7.16M(m)$12.90M(m)-$12.17M
2019-06-30(m)$7.38M(m)$10.59M(m)-$9.46M
2018-06-30(m)$3.04M(m)$4.73M(m)-$4.43M
2017-06-30(m)$765.00K(m)$1.18M(m)-$1.25M

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$282.02M$43.25M$105.29M$165.00M-$15.09M$153.43M
2024-09-30$199.38M$40.05M$82.34M$175.00M$3.07M$43.68M
2023-09-30$8.56M$35.06M$73.64M$121.42M$0.00$2.24M
2022-09-30$0.00$31.72M$53.70M$110.42M(m)-$107.92M
2021-09-30(m)$18.88M(m)$46.40M(m)-$47.76M
2020-09-30(m)$12.26M(m)$22.58M(m)-$21.78M
2019-09-30(m)$11.27M(m)$15.93M(m)-$13.73M
2018-09-30(m)$4.96M(m)$7.70M(m)-$7.18M
2017-09-30(m)$2.12M(m)$3.27M(m)-$6.53M
2016-09-30(m)$339.00K(m)$523.00K(m)-$523.00K

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$389.13M$58.05M$146.74M$227.84M-$15.36M$204.83M
2024-12-31$290.51M$53.58M$113.63M$224.77M$6.20M$89.16M
2023-12-31$50.70M$46.43M$98.29M$160.32M$1.97M$10.93M
2022-12-31$0.00$42.46M$77.73M$145.20M$0.00-$139.97M
2021-12-31$0.00$27.88M(m)$68.28M$0.00-$69.57M
2020-12-31(m)$17.94M(m)$33.00M$0.00-$32.17M
2019-12-31(m)$15.62M(m)$22.08M$0.00-$19.09M
2018-12-31(m)$7.76M(m)$11.92M$0.00-$10.89M
2017-12-31(m)$3.21M(m)$4.77M$0.00-$7.92M
2016-12-31(m)$741.00K(m)$1.14M(m)-$1.15M

Similar stocks

Stock NameCountryMarket CapPE Ratio
REPLIGEN CORP (RGEN)United States$10.755B185.31
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Immunovant, Inc. (IMVT)United States$7.028B-14.78
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
CG Oncology, Inc. (CGON)United States$6.095B-27.95